Flurithromycin (Pierrel S.p.A.), an (8S)-8-fluoroerythromycin, shows the same spectrum of antimicrobial activity as does erythromycin and the same activity in vitro (4, 9) . Preliminary information on the kinetics of this drug in healthy volunteers suggests that flurithromycin has good bioavailability and attains suitable levels in serum (1) . We investigated the pharmacokinetics of flurithromycin after single and multiple doses and studied its penetration into bone, soft tissue, lung, and pericardial fluid in surgery patients. Since the antibacterial activity of antibiotics in vivo cannot be predicted only from activity in vitro and free concentrations in serum, we studied the relationship between free flurithromycin concentrations in serum and levels in interstitial fluid, calculated from total drug content in tissue, and consequently the difference in drug penetration into different tissues.
MATERIALS AND METHODS
Bone and soft tissue. Twelve male patients (20 to 31 years old and weighing 58 to 72 kg) undergoing maxillofacial surgery were included in the study. Each patient had a normal clinical examination, normal hematological findings, and normal renal and liver function tests. None of the subjects took other drugs or antibiotics at least 2 weeks before the surgery. Informed consent was obtained from each patient before flurithromycin administration. Each patient received a total of 10 doses of 500 mg of antibiotic at 8-h intervals. Blood samples were taken after one administration of 500 mg of flurithromycin and on the morning of day 4 after the last (10th) dose, during surgery. Blood samples were taken at 0, 0.25, 0.5, 1, 1.5, 3, and 8 h after drug administration.
Bone and soft tissue samples, obtained from each patient at 1, 1.5, 2, and 3 h after drug administration, were pulverized with a Spex freezer mill and diluted 1:3 in 0.1 M phosphate buffer (pH 8) before assay.
Lung tissue and pericardial fluid. Nine male patients (56 to 68 years old and weighing 78 to 47 kg) undergoing thoracot-* Corresponding author. omy were studied. Informed consent was obtained from each patient. The patients had normal renal and hepatic function, and none had received any antibiotics in the month before the surgery.
These patients received a total of seven doses of 500 mg of flurithromycin at 8-h intervals. Blood samples were taken after one administration of a 500-mg dose and on the morning of day 3 after the last dose. Blood samples were taken at 0, 0.5, 1, 2, 4, 6, and 7 h after drug administration.
Lung tissue samples were collected at 1.5, 2.6, 4, 5, and 7 h after drug administration and homogenized in an equal volume of 0.1 M phosphate buffer (pH 8). The homogenates were centrifugated at 1,200 x g in a refrigerated centrifuge, and the supernatants were immediately assayed. Pericardial fluid samples were collected at 1.5, 3.5, 3.8, 5.7, and 7 h during surgery and assayed in toto.
Drug assay and kinetic model. All samples were assayed within 2 h of collection by a microbiological method, using antibiotic medium 1 and Micrococcus luteus ATCC 9341 as the indicator organism. Serum, tissue, and pericardial fluid samples were assayed against standards prepared in serum, tissue, and fluid samples of subjects who had received no antibiotic therapy. The limit of detection of the assay was 0.03 ,g/ml. The assay had a coefficient of variation of 6.5% and a mean relative error of 8%. Assays of hemoglobin in tissues and correction of flurithromycin concentrations for blood contamination were performed according to Kroening et al. (8) .
The sampling period was long enough to allow drug levels in serum after one dose to approach zero or at least low values. Free concentrations in serum were calculated from the total levels in serum by correction for protein binding, which amounted to 70% (G. Bonardi, unpublished data) for flurithromycin. Binding of flurithromycin to serum protein is independent of drug concentration.
A model was assumed in which free antibiotic can diffuse passively from plasma to interstitial fluid. Both the volume of interstitial fluid (as a fraction of total tissue volume) and the binding to other tissue constituents are unknown. In the model used by us, the following equations hold: (2) in which Cdt is the area under the concentration-time curve (AUC) when Ci returns to zero after the first dose. Equation 1 leads to C1dt= J Cpdt (3) The relationship between tissue content and concentrations in interstitial fluid and other tissue components is expressed by Ct = fiCi + (1 D)Cr (4) in which Ct is total tissue content, f; is the volume fraction of interstitial fluid, and Cr is the mean concentration in other tissue components. Combination of equations 3 and 4 leads to AUC,/AUCp = (R -f1)1(1 -f]), in which R = AUCt/ AUCp. In these equations, the subscripts r, p, i, and t refer to measurements in other tissue components, in plasma, in interstitial fluid, and in tissue, respectively.
The predicted accumulation factor (Rp) was calculated by dividing 1 by the quantity (1 -e-T), in which ,B was determined from the first dose and T was the dose interval. The observed accumulation factor (Ro) was determined by the ratio of the AUC from 0 h to infinity (AUC_OO) for the last dose to the AUC0OC for the first dose.
Pharmacokinetic parameters were calculated by conventional means from the plasma concentration-time data collected in a single-dose portion of the study and after administration of the last dose of the multiple-dose regimen according to the formulas of Gibaldi and Perrier (5).
RESULTS
The serum and tissue curves provide an indication of the penetration of flurithromycin into bone, soft tissue, lung, and pericardial fluid, elimination of the drug, and the relationship between drug levels in blood and tissues. After correction for protein binding, the free concentrations in serum were calculated. Fig. 1 and 2 show the curves of the total free concentrations in serum after single and multiple doses of flurithromycin and drug content in lung, bone, soft tissue, and pericardial fluid. These curves are based on the means of the results of two values at each time point; standard deviations were not calculated.
The AUC from 0 to 7 h for lung samples was 23.4 ,ug h/g, and the AUCs from 0 to 3 h for bone and soft tissue samples were 2.4 and 1.93 ,ug-h/g, respectively. The ratios of flurithromycin AUC from 0 to T in tissues to that in serum were 2.15 for lung, 0.58 for bone, and 0.46 for soft tissue.
Moreover, the AUC,,s in tissue (in micrograms hour per gram) were 54.8 for lung, 31 for bone, and 7.0 for soft tissue.
The ratios (R) of AUCo. in tissues to that in serum were 8.3 for lung, 3.6 for bone, and 0.8 for soft tissue.
Concentrations in the interstitial fluid at individual time points were calculated by dividing through R total content in tissues. Figure 3 shows the curves of the free antibiotic concentrations in serum and the calculated concentrations in interstitial fluid. The calculated contents in the interstitial fluid of bone and lung tissues were similar to the free concentrations in serum, whereas concentrations in soft tissue were very different.
The pharmacokinetic parameters (mean and standard deviation) for each group after the first and last doses of flurithromycin are presented in Table 1 . The mean residence times were 10.2 h for group 1 and 8.3 h for group 2. The ratio of the AUC during a dose interval to the AUC for the first dose averaged 0.25 for group 1 and 0.67 for group 2. The predicted and observed accumulation factors were 2.2 and 1.8, respectively, for group 1 and 2.0 and 1.4 for group 2.
DISCUSSION
The pharmacokinetics of flurithromycin and the relationship between free flurithromycin concentration in serum and levels in tissues were studied in patients undergoing thoracotomy or maxillofacial surgery. In four patients undergoing maxillofacial surgery and in one patient undergoing thoracotomy, treatment was suspended because of gastrointesti- nal side effects. The correlation between incidence or severity of gastrointestinal symptoms, flurithromycin concentration in plasma, and therapeutic effect has not been studied.
The pharmacokinetic data derived from this study agree with preliminary results discussed by Bonardi et al. (1) . The serum half-lives of flurithromycin were similar in the two groups, ranging from 7.7 h after 1 dose to 9.9 h after 10 doses. This study shows that higher concentrations of flurithromycin in serum and tissues were achieved than would be expected from a comparable oral dose of erythromycin. Comparative crossover studies should be performed to confirm this point. Flurithromycin is rapidly absorbed, giving a peak level in serum by 1 to 2 h. In general, the observed accumulation factor was close to the predicted accumulation factor. For both groups, the mean elimination half-life Qf wumg/mI flurithromycin obtained from the last dose was similar to that obtained from the first dose, consistent with linear and predictable accumulation.
In pericardial fluid, the flurithromycin curve follows the total-serum curve. The protein content of this fluid reflects the similar behavior of the drug observed in serum'. The ratio of content in total tissue and free levels in serum ranged greatly in the tissues examined, being very high in bone and lung tissues. In these cases, flurithromycin is present not only in interstitial fluid but also in cells, and it appears that differences in tissue binding may play a role. The large volume of distribution is in accordance with these values.
The amount of antibiotic per gram of tissue is not equal to the concentration of free, potentially active antibiotic. Content in total tissue is determined by the free aqueous antibiotic concentration, the tissue-bound fraction of the drug, and In experiments with animals, Grady and Stern (6) found detectable erythromycin concentrations in bone material from rats. Sandberg Sorensen et al. (10) , studying humans, detected erythromycin concentrations in all narrow and cancellous bone specimens which exceeded the MIC of 0.25 to 0.5 ,ug/ml for susceptible strains of Staphylococcus aureus.
In soft tissue, the drug content in interstitial fluid is higher than the free levels in serum and similar to total content in tissue. It is probable that the presence of inflammation or exudate and consequently of phagocytes in the interstitial fluid of soft tissue and the ability of macrolides to penetrate into phagocytes account for this high content. In alveolar macrophages, the concentrations of macrolides in intracellular fluid are 9 to 23 times higher than the concentrations in extracellular fluid (7) . Even if high concentrations are achieved intracellularly, the antimicrobial activity of the antibiotic against phagocytosed bacteria is difficult to prove. It is probable that for bacteriostatic drugs such as macrolides, both very high and prolonged concentrations in tissue are necessary for a favorable therapeutic result.
